Incyte Corporation has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Monjuvi® (tafasitamab-cxix), in combination with rituximab and lenalidomide, for the treatment of adult patients with relapsed or refractory follicular lymphoma $(FL)$. This marks the second approved indication for Monjuvi in the United States. The approval comes as a significant development for patients with relapsed or refractory FL, offering a new option that targets CD19 and CD20 with an immunotherapy combination. Incyte is committed to supporting patients through IncyteCARES, a program that provides personalized support, including financial assistance and educational resources.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.